Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mandatory Mail Will Help Replace Federal Contract, Medco Says

Executive Summary

Medco is counting on a movement by private clients towards mandatory mail plans to make up for its loss of the Federal Employee's Health Benefit Program mail service contract

You may also be interested in...



Caremark PCS Merger Wins Big Customer; Blues Move FEP Mail From Medco

Caremark will take over the mail service pharmacy program for the Blue Cross/Blue Shield Association Federal Employees Program effective Jan. 1

Medco/Oxford Services Contract Is Basis Of “Kickback” Allegation In DoJ Suit

Medco's $83 mil. payment to Oxford Health Plans for consultative and information services is the basis for the Philadelphia U.S. Attorney's "kickback" allegations against the PBM

WellPoint/Anthem Merger Enhances Number Four PBM, Creates Big Buyer

WellPoint and Anthem see a "significant opportunity" to squeeze pharmaceutical prices as a result of the proposed merger between the two companies

Related Content

UsernamePublicRestriction

Register

PS043869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel